Table 4.
|
|
LL-37 level in ICF (ng/million cells) |
||
---|---|---|---|---|
Day-0 | Day-4 | Day-8 | ||
Group-I |
NAL |
0.24 ± 0.07 |
0.23 ±0.11 |
0.18 ± 0.12 |
Group-II |
NAL |
0.28 ± 0.04 |
0.49 ± 0.16 1,2 |
0.33 ± 0.11 |
Group-III |
NAL |
0.31 ± 0.11 |
0.25 ± 0.02 |
0.17 ± 0.06 |
Group-IV |
NAL |
0.27 ± 0.14 |
0.21 ± 0.02 |
0.68 ± 0.32 3,4 |
Group-V | NAL | 0.19 ± 0.08 | 0.37 ± 0.07 | 0.27 ± 0.15 |
Note: Group-I: 250 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-II: 500 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-III: 1000 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-IV: 500 mg PB b.d.; Group-V: 5000 IU vitamin D3 o.d. Data expressed as Mean ± Standard Deviation. One Way Analysis of Variance (ANOVA) method was used for statistical analysis. Differences are significant, when p < 0.05. Difference between, 1Group-II and -I within day-4 (p = 0.05); 2Group-II and -IV within day-4 (p = 0.03); 3Group-IV and -I within day-8 (p = 0.04); 4Group-IV and-III within day-8 (p = 0.036). ICF, Intracellular fluid; PB, Phenylbutyrate; NAL, Non-adherent lymphocytes; b.d., Twice daily; o.d., Once daily.